{{Rsnum
|rsid=7157080
|Gene=AP4S1
|Chromosome=14
|position=31084514
|Orientation=plus
|GMAF=0.2406
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(G;G)
|geno2=(G;T)
|geno3=(T;T)
|Gene_s=AP4S1
}}{{ population diversity
| geno1=(G;G)
| geno2=(G;T)
| geno3=(T;T)
| CEU | 4.5 | 38.4 | 57.1
| HCB | 0.0 | 5.8 | 94.2
| JPT | 0.0 | 3.6 | 96.4
| YRI | 34.7 | 44.2 | 21.1
| ASW | 28.1 | 36.8 | 35.1
| CHB | 0.0 | 5.8 | 94.2
| CHD | 0.0 | 5.5 | 94.5
| GIH | 3.0 | 18.0 | 79.0
| LWK | 39.1 | 43.6 | 17.3
| MEX | 3.4 | 19.0 | 77.6
| MKK | 11.5 | 51.3 | 37.2
| TSI | 2.9 | 33.3 | 63.7
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs7157080
|Name_s=
|Gene_s=AP4S1
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 89. Study population/ethnicity: 89 Yorubans. Significance metric(s): p = 0.00003. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109321
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs7157080
|overall_frequency_n=37
|overall_frequency_d=128
|overall_frequency=0.289062
|n_genomes=22
|n_genomes_annotated=0
|n_haplomes=33
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | Illumina Human 1M}}
{{on chip | NatGeo2}}